DGIdb - GNA11 Gene Record

GNA11 2767 Clinically Actionable

Alternate Names:

2767
G PROTEIN SUBUNIT ALPHA 11
GNA11
FBH
FBH2
FHH2
GNA-11
HHC2
HYPOC2
139313
4379
ENSG00000088256
OTTHUMG00000180631
2308
HG1K

Gene Info:

Gene Biotype	PROTEIN_CODING

(5 More Sources)

Gene Categories: Category Details

CLINICALLY ACTIONABLE

Publications:

Carita et al., 2016, Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma., Oncotarget
Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene
Patel et al., 2011, Therapeutic implications of the emerging molecular biology of uveal melanoma., Clin. Cancer Res.
Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
Landis et al., 1989, GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours., Nature
Khalili et al., 2012, Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner., Clin. Cancer Res.
MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
Kalinec et al., 1992, Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells., Mol. Cell. Biol.
Ho et al., 2012, Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype., PLoS ONE
Van Raamsdonk et al., 2010, Mutations in GNA11 in uveal melanoma., N. Engl. J. Med.
von Euw et al., 2012, Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines., Mol. Cancer
Daud et al., 2017, Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma., Br. J. Cancer

CGM-097 GNA11

Interaction Score: 2.58

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + CGM097

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB
SELUMETINIB GNA11

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

Clinical Status early trials

Pathway activation

Variant Effect gain-of-function

PMIDs:
21444680 26619011 24141786 2549426 22733540 25157968 1328859 22808163 21083380

Sources:
DoCM
TAK-733 GNA11

Interaction Score: 1.93

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22515704

Sources:
JAX-CKB
BINIMETINIB GNA11

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MEK162 + AEB071

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
27507190 24141786

Sources:
JAX-CKB
CABOZANTINIB GNA11

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28103611

Sources:
CIViC
SOTRASTAURIN GNA11

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + CGM097

Approval Status Preclinical - Pdx & cell culture

Response Type predicted – sensitive

PMIDs:
27507190 24141786

Sources:
JAX-CKB
EVEROLIMUS GNA11

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + Everolimus

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB
TRAMETINIB GNA11

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22733540

Sources:
JAX-CKB

Ensembl: ENSG00000088256
- Version: 101_38
Alternate Names:

GNA11 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: GNA11

Version: 27-September-2017

Alternate Names:

2767 CKB Entrez Id

GNA11 CKB Gene Synonym

FBH CKB Gene Synonym

Gene Info:

Publications:

Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene

Carita et al., 2016, Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma., Oncotarget

Khalili et al., 2012, Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner., Clin. Cancer Res.

CIViC: GNA11

Version: 14-September-2020

Alternate Names:

2767 Entrez Gene ID

2308 CIViC Gene ID

Gene Info:

Publications:

Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene

Daud et al., 2017, Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma., Br. J. Cancer

DoCM: GNA11

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.

Landis et al., 1989, GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours., Nature

Ho et al., 2012, Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype., PLoS ONE

Tempus: GNA11
- Version: 11-November-2018
Alternate Names:

GNA11 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
MskImpact: GNA11
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: GNA11
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: GNA11
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: GNA11
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

combination therapy	AEB071 + CGM097
Indication/Tumor Type	uveal melanoma
Response Type	predicted – sensitive

Clinical Status	early trials
Pathway	activation
Variant Effect	gain-of-function

combination therapy	MEK162 + AEB071
Indication/Tumor Type	uveal melanoma
Response Type	sensitive

combination therapy	AEB071 + CGM097
Approval Status	Preclinical - Pdx & cell culture
Response Type	predicted – sensitive

combination therapy	AEB071 + Everolimus
Indication/Tumor Type	uveal melanoma
Response Type	predicted – sensitive

GNA11 Gene Record

GNA11 2767 Clinically Actionable

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AEB071 + CGM097 Indication/Tumor Type uveal melanoma Response Type predicted – sensitive

PMIDs: 27507190

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Clinical Status early trials Pathway activation Variant Effect gain-of-function

PMIDs: 21444680 26619011 24141786 2549426 22733540 25157968 1328859 22808163 21083380

Sources: DoCM

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type uveal melanoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 22515704

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy MEK162 + AEB071 Indication/Tumor Type uveal melanoma Response Type sensitive

PMIDs: 27507190 24141786

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28103611

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AEB071 + CGM097 Approval Status Preclinical - Pdx & cell culture Response Type predicted – sensitive

PMIDs: 27507190 24141786

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AEB071 + Everolimus Indication/Tumor Type uveal melanoma Response Type predicted – sensitive

PMIDs: 27507190

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type uveal melanoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 22733540

Sources: JAX-CKB

Ensembl: ENSG00000088256

Alternate Names: GNA11 Ensembl Gene Name

Gene Info: Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: GNA11

Alternate Names: 2767 CKB Entrez Id GNA11 CKB Gene Synonym FBH CKB Gene Synonym

Gene Info:

CIViC: GNA11

Alternate Names: 2767 Entrez Gene ID 2308 CIViC Gene ID

Gene Info:

Publications: Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene Daud et al., 2017, Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma., Br. J. Cancer

DoCM: GNA11

Alternate Names:

Gene Info:

Tempus: GNA11

Alternate Names: GNA11 Gene Symbol

Gene Info:

Gene Categories: CLINICALLY ACTIONABLE

Publications:

MskImpact: GNA11

Alternate Names:

Gene Info:

Gene Categories: CLINICALLY ACTIONABLE

Publications:

FoundationOneGenes: GNA11

Alternate Names:

Gene Info:

Gene Categories: CLINICALLY ACTIONABLE

Publications:

CarisMolecularIntelligence: GNA11

Alternate Names:

Gene Info:

Gene Categories: CLINICALLY ACTIONABLE

Publications:

Oncomine: GNA11

Alternate Names:

Gene Info:

Gene Categories: CLINICALLY ACTIONABLE

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + CGM097

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Clinical Status early trials

Pathway activation

Variant Effect gain-of-function

PMIDs:
21444680 26619011 24141786 2549426 22733540 25157968 1328859 22808163 21083380

Sources:
DoCM

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22515704

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MEK162 + AEB071

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
27507190 24141786

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
28103611

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + CGM097

Approval Status Preclinical - Pdx & cell culture

Response Type predicted – sensitive

PMIDs:
27507190 24141786

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + Everolimus

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22733540

Sources:
JAX-CKB

Alternate Names:

GNA11 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

2767 CKB Entrez Id

GNA11 CKB Gene Synonym

FBH CKB Gene Synonym

Alternate Names:

2767 Entrez Gene ID

2308 CIViC Gene ID

Publications:

Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene

Daud et al., 2017, Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma., Br. J. Cancer

Alternate Names:

GNA11 Gene Symbol

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE